Literature DB >> 30761943

Intravenous administration of multipotent stromal cells and bone allograft modification to enhance allograft healing.

Sharada Paudel1, Wen-Han Lee1, Moses Lee1, Talal Zahoor1, Reed Mitchell1, Shang-You Yang2, Haiqing Zhao3, Lew Schon1, Zijun Zhang1.   

Abstract

Aim: This study investigated a coordinated strategy of revitalizing bone allograft with circulating multipotent stromal cells (MSCs). Materials & methods: After chemotactic and releasing assessments, stromal cell-derived factor 1 and platelet-derived growth factor BB in copolymers were coated on the bone allograft (AlloS-P). Allograft coated with copolymers alone (Allo), as controls, or AlloS-P was implanted into the femur of athymic mice, which received intravenous injections of human MSCs or saline at weeks 1, 2 and 3.
Results: At week 8, the total callus volume (both cartilaginous and bony callus) around the allograft was the largest in the AlloS-P + MSC group (p < 0.05).
Conclusion: Coating bone allograft with stromal cell-derived factor 1 and platelet-derived growth factor BB and intravenous injections of MSCs improved allograft incorporation.

Entities:  

Keywords:  allograft; bone; intravenous injection; multipotent stromal cells; stromal cell-derived factor 1

Mesh:

Year:  2019        PMID: 30761943      PMCID: PMC8010790          DOI: 10.2217/rme-2018-0063

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  55 in total

Review 1.  Bone grafts and their substitutes.

Authors:  Y Fillingham; J Jacobs
Journal:  Bone Joint J       Date:  2016-01       Impact factor: 5.082

2.  Allograft bone decreases in strength in vivo over time.

Authors:  Donna L Wheeler; William F Enneking
Journal:  Clin Orthop Relat Res       Date:  2005-06       Impact factor: 4.176

Review 3.  Bone grafts and bone graft substitutes in orthopaedic trauma surgery. A critical analysis.

Authors:  William G De Long; Thomas A Einhorn; Kenneth Koval; Michael McKee; Wade Smith; Roy Sanders; Tracy Watson
Journal:  J Bone Joint Surg Am       Date:  2007-03       Impact factor: 5.284

Review 4.  Allograft reconstruction in malignant bone tumors: indications and limits.

Authors:  Kevin A Raskin; Francis Hornicek
Journal:  Recent Results Cancer Res       Date:  2009

5.  A novel strategy incorporated the power of mesenchymal stem cells to allografts for segmental bone tissue engineering.

Authors:  Xiao Hui Zou; Hong Xin Cai; Zi Yin; Xiao Chen; Yang Zi Jiang; Hu Hu; Hong Wei Ouyang
Journal:  Cell Transplant       Date:  2009       Impact factor: 4.064

Review 6.  In situ tissue regeneration: chemoattractants for endogenous stem cell recruitment.

Authors:  Wendy S Vanden Berg-Foels
Journal:  Tissue Eng Part B Rev       Date:  2013-07-11       Impact factor: 6.389

7.  Intravenous Injection of Clinical Grade Human MSCs After Experimental Stroke: Functional Benefit and Microvascular Effect.

Authors:  Anack Moisan; Isabelle Favre; Claire Rome; Florence De Fraipont; Emmanuelle Grillon; Nicolas Coquery; Herv Mathieu; Virginie Mayan; Bernadette Naegele; Marc Hommel; Marie-Jeanne Richard; Emmanuel Luc Barbier; Chantal Remy; Olivier Detante
Journal:  Cell Transplant       Date:  2016-02-26       Impact factor: 4.064

8.  Remote ischemic postconditioning enhances cell retention in the myocardium after intravenous administration of bone marrow mesenchymal stromal cells.

Authors:  Qin Jiang; Peng Song; Enshi Wang; Jun Li; Shengshou Hu; Hao Zhang
Journal:  J Mol Cell Cardiol       Date:  2013-01-03       Impact factor: 5.000

9.  New opportunities for fracture healing detection: Impedance spectroscopy measurements correlate to tissue composition in fractures.

Authors:  Monica C Lin; Frank Yang; Safa T Herfat; Chelsea S Bahney; Meir Marmor; Michel M Maharbiz
Journal:  J Orthop Res       Date:  2017-06-09       Impact factor: 3.494

10.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.